WVE - ウェ―ブ・ライフ・サイエンシズ （WAVE Life Sciences Ltd.） ウェ―ブ・ライフ・サイエンシズWVEのチャート
WVEの企業情報
| symbol | WVE |
|---|---|
| 会社名 | Wave Life Sciences Ltd （ウェ―ブ・ライフ・サイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ウェーブ・ライフ・サイエンス（WAVE Life Sciences Ltd.）は遺伝子医薬品会社である。同社は合成化学薬品開発プラットフォームを通じて遺伝的定義された疾患向けの核酸治療候補製品パイプラインを設計、開発と商業化する。同社は疾患を促進するタンパク質の発現または機能不全の変異体タンパク質の産生を機能性タンパク質の産生に変換するために遺伝的欠陥を標的とするオリゴヌクレオチドを開発する。同社は核酸治療薬stereopureを開発する。stereopureオリゴヌクレオチドは各連結部に3次元配向で配置された原子を有する分子を含む。同社はハンチントン病（HD）とデュシェンヌ型筋ジストロフィー（DMD）にある3つのプログラムと3つの追加的開発候補製品を有する。 ウェ―ブ・ライフ・サイエンシズはシンガポ―ルのバイオ医薬品企業。臨床の前段階の研究に従事し、主に核酸医薬に焦点を当て根治が難しい病気に対する治療を目指す。遺伝子治療において、難病を進行させるタンパク質の発現を減らす方法、または機能不全の変異体タンパク質を機能的なタンパク質に変える方法などを研究・開発する。 Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. |
| 本社所在地 | 7 Straits View #12-00 Marina One East Tower 018936 SGP |
| 代表者氏名 | Gregory L. Verdine グレゴリー・L・ヴェルディネ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | -620784 |
| 設立年月日 | 41091 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 168人 |
| url | www.wavelifesciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/wve |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -126.02700 |
| 終値（lastsale） | 42.98 |
| 時価総額（marketcap） | 1260271035.66 |
| 時価総額 | 時価総額（百万ドル） 1300.736 |
| 売上高 | 売上高（百万ドル） 8.65300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 167.179 |
| 当期純利益 | 当期純利益（百万ドル） -127.48100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Wave Life Sciences Ltd revenues increased from $1.5M to $6.3M. Net loss increased 56% to $71.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 82% to $61.7M (expense) General and administrative increase of 35% to $16.9M (expense). |
WVEのテクニカル分析
WVEのニュース
Have you been able to find a good deal on Wave Life Sciences Ltd.’s shares? 2022/11/24 17:24:00 US Post News
As of Wednesday, Wave Life Sciences Ltd.’s (NASDAQ:WVE) stock closed at $4.21, up from $4.10 the previous day. While Wave Life Sciences Ltd. has overperformed by 2.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE rose by 6.05%, with highs and lows ranging from $5.31 […]
Investing in Wave Life Sciences Ltd. (WVE) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/14 16:40:00 US Post News
The share price of Wave Life Sciences Ltd. (NASDAQ:WVE) fell to $3.64 per share on Friday from $4.17. While Wave Life Sciences Ltd. has underperformed by -12.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE fell by -23.21%, with highs and lows ranging from $5.31 […]
Wave Life Sciences Ltd. (WVE) Q3 2022 Earnings Call Transcript 2022/11/10 19:55:23 Seeking Alpha
Wave Life Sciences Ltd. (NASDAQ:NASDAQ:WVE) Q3 2022 Earnings Conference Call November 10, 2022 08:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President…
Wave Life Sciences Ltd. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:WVE) 2022/11/10 18:26:37 Seeking Alpha
The following slide deck was published by Wave Life Sciences Ltd.
Wave Life Sciences: Q3 Earnings Snapshot 2022/11/10 13:30:42 One News Page
SINGAPORE (AP) _ Wave Life Sciences Pte. Ltd. (WVE) on Thursday reported a loss of $39 million in its third quarter. The Singapore-based company said it had a loss of 42 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks …
Have you been able to find a good deal on Wave Life Sciences Ltd.’s shares? 2022/11/24 17:24:00 US Post News
As of Wednesday, Wave Life Sciences Ltd.’s (NASDAQ:WVE) stock closed at $4.21, up from $4.10 the previous day. While Wave Life Sciences Ltd. has overperformed by 2.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE rose by 6.05%, with highs and lows ranging from $5.31 […]
Investing in Wave Life Sciences Ltd. (WVE) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/14 16:40:00 US Post News
The share price of Wave Life Sciences Ltd. (NASDAQ:WVE) fell to $3.64 per share on Friday from $4.17. While Wave Life Sciences Ltd. has underperformed by -12.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE fell by -23.21%, with highs and lows ranging from $5.31 […]
Wave Life Sciences Ltd. (WVE) Q3 2022 Earnings Call Transcript 2022/11/10 19:55:23 Seeking Alpha
Wave Life Sciences Ltd. (NASDAQ:NASDAQ:WVE) Q3 2022 Earnings Conference Call November 10, 2022 08:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President…
Wave Life Sciences Ltd. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:WVE) 2022/11/10 18:26:37 Seeking Alpha
The following slide deck was published by Wave Life Sciences Ltd.
Wave Life Sciences: Q3 Earnings Snapshot 2022/11/10 13:30:42 One News Page
SINGAPORE (AP) _ Wave Life Sciences Pte. Ltd. (WVE) on Thursday reported a loss of $39 million in its third quarter. The Singapore-based company said it had a loss of 42 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks …
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday 2022/10/10 09:28:51 Benzinga
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY ) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday. Inventiva S.A. (NASDAQ: IVA ) climbed 69.5% to settle at $7.05 after gaining around 10% on Thursday. Minim, Inc. (NASDAQ: MINM ) rose 50.9% to close at $0.32 on Friday. Minim, during August, posted a Q2 loss of $0.10 per share. New Concept Energy, Inc. (NYSE: GBR ) gained 30% to close at $1.56. Abeona Therapeutics Inc. (NASDAQ: ABEO ) climbed 25.3% to close at $4.41. Abeona Therapeutics recently announced completion of patient follow-up in pivotal Phase 3 VIITAL study of EB-101. Aehr Test Systems (NASDAQ: AEHR ) climbed 23.9% to close at $17.19 after the company announced better-than-expected Q1 EPS and sales results and issued guidance. Brookdale Senior Living Inc. (NYSE: BKD ) gained 20% to close at $4.81. Brookdale Senior Living is said to explore a sale, Bloomberg reported. Ambac Financial Group, Inc (NASDAQ: AMBC ) climbed 15.6% to close at $14.80 after the company announced it settled its RMBS litigations against Bank of America for $1.84 billion. eMagin Corporation (NYSE: EMAN ) rose 15.6% to close at $0.7170. eMagin, in August, reported second-quarter FY22 revenue growth of 14% year-on-year to $7.2 million.
Wave Life Sciences (WVE) Investor Presentation - Slideshow (NASDAQ:WVE) 2022/10/06 17:15:51 Seeking Alpha
The following slide deck was published by Wave Life Sciences Ltd.
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference 2022/09/27 12:30:00 GlobeNewswire
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan’s 6th Annual Genetic Medicines Conference in New York City on Tuesday, October 4, 2022, at 3:15 p.m. ET.
Wave Life Sciences Ltd. (NASDAQ:WVE): Buy, Sell Or Hold At $3.91? 2022/09/24 13:00:00 Marketing Sentinel
In last trading session, Wave Life Sciences Ltd. (NASDAQ:WVE) saw 0.44 million shares changing hands with its beta currently measuring -0.57. Company’s recent per share price level of $3.91 trading at -$0.01 or -0.26% at ring of the bell on the day assigns it a market valuation of $354.21M. That closing price of WVE’s stock … Wave Life Sciences Ltd. (NASDAQ:WVE): Buy, Sell Or Hold At $3.91? Read More »
Wave Life stock rises as WVE-003 shows promise in interim data of Huntington''s disease trial 2022/09/20 13:18:54 Seeking Alpha
Wave Life Sciences (WVE) said a single dose of 30 mg or 60 mg WVE-003 helped reduce mutant huntingtin (mHTT) protein in cerebrospinal fluid ((CSF)) in patients with Huntington''s…